Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020968 · ClinicalTrials.gov registry record · Phase 2
Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
A Phase 2 study of Dilated Cardiomyopathy, sponsored by Vericel Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 3
- Study locations
NCT01020968: Completed Phase 2 study of Dilated Cardiomyopathy, sponsored by Vericel Corporation.
NCT01020968 is a Phase 2 study of Dilated Cardiomyopathy that has completed, run by Vericel Corporation. The registered enrollment target is 22 participants, below the 259-participant average among 6 other Dilated Cardiomyopathy trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01020968, a Phase 2 study of Dilated Cardiomyopathy, has completed, sponsored by Vericel Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is designed to assess the safety profile and the efficacy of cardiac repair cells (CRCs) administered via catheter in treating patients with dilated cardiomyopathy (DCM).
Conditions Studied
Interventions
- OTHER Vehicle Control
- BIOLOGICAL Ixmyelocel-T
Study Locations (3)
Minnesota
- Minneapolis Heart Institute - Minneapolis
Ohio
- University Hospitals, Case Western Reserve University - Cleveland
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-12-05 |
| Phase | Phase 2 |
What the finished NCT01020968 record still lists
NCT01020968 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 259-participant average among 6 other Dilated Cardiomyopathy trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Dilated Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Control is the first listed.
NCT01020968 reports a single indexed study location in Minnesota, Ohio, Utah.
Frequently Asked Questions
What is clinical trial NCT01020968 about?
NCT01020968 is a clinical study titled "Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy". This study is designed to assess the safety profile and the efficacy of cardiac repair cells (CRCs) administered via catheter in treating patients with dilated cardiomyopathy (DCM).
What is the current status of trial NCT01020968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2009-12. Estimated completion is 2013-12-05.
What conditions does trial NCT01020968 study?
This clinical trial studies the following conditions: Dilated Cardiomyopathy.
What interventions are being tested in trial NCT01020968?
The interventions under investigation include: Vehicle Control (OTHER), Ixmyelocel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT01020968?
This trial is sponsored by Vericel Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01020968 being conducted?
This trial has 3 study locations across Minnesota, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dilated Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
RECRUITING · Phase 1
-
Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
RECRUITING · NA
-
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
RECRUITING · NA
-
Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study
RECRUITING
-
Pediatric Cardiomyopathy Mutation Analysis
RECRUITING
-
Nesiritide - Dilated Cardiomyopathy
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia